

# ***Caveolin-1* mediates tumor cell migration and invasion and its regulation by *miR-133a* in head and neck squamous cell carcinoma**

NIJIRO NOHATA<sup>1,2</sup>, TOYOYUKI HANAZAWA<sup>2</sup>, NAOKO KIKKAWA<sup>1,2</sup>, MURADIL MUTALLIP<sup>1,2</sup>, LISA FUJIMURA<sup>3</sup>, HIROFUMI YOSHINO<sup>4</sup>, KAZUMORI KAWAKAMI<sup>4</sup>, TAKESHI CHIYOMARU<sup>4</sup>, HIDEKI ENOKIDA<sup>4</sup>, MASAYUKI NAKAGAWA<sup>4</sup>, YOSHITAKA OKAMOTO<sup>2</sup> and NAOHIKO SEKI<sup>1</sup>

Departments of <sup>1</sup>Functional Genomics, <sup>2</sup>Otorhinolaryngology/Head and Neck Surgery, Graduate School of Medicine, <sup>3</sup>Biomedical Research Center, Chiba University, Chiba; <sup>4</sup>Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan

Received September 2, 2010; Accepted October 27, 2010

DOI: 10.3892/ijo\_00000840

**Abstract.** MicroRNAs (miRNAs) are small non-coding RNAs of approximately 22 nucleotides that can function as oncogenes or tumor suppressors in human cancer. Down-regulation of the miRNA *miR-133a* in many type of cancers, and a reduction of cell proliferation, migration, and invasion upon over-expression, suggests that *miR-133a* is a tumor suppressor. In this study, genome-wide gene expression analysis of HNSCC cells that over-express *miR-133a* showed that *caveolin-1* (*CAV1*), a multifunctional scaffolding protein, is down-regulated, a result that was confirmed by real-time PCR and Western blot analysis. A luciferase reporter assay revealed that *miR-133a* is directly bound to *CAV1* mRNA. Cancer cell migration and invasion were significantly inhibited in HNSCC cells transfected with si-*CAV1*. Therefore, *CAV1* functions as an oncogene in HNSCC. The identification of tumor suppressive miRNAs and their target genes could provide new insights into potential mechanism of HNSCC carcinogenesis.

## **Introduction**

MicroRNAs (miRNAs) are small non-coding RNAs with a length of approximately 22 nucleotides. They regulate gene expression by mRNA cleavage and at the post-transcriptional level by translational suppression (1). They play important roles in various biological and metabolic processes, including development, differentiation, signal transduction, cell maintenance, and cancer (1,2). Bioinformatic predictions indicate

that miRNAs regulate more than 30% of the protein coding genes (3). It is estimated that approximately 1,000 miRNAs exist in the vertebrate genome. So far, 1048 human miRNAs are registered at miRBase release 16.0 (<http://microrna.sanger.ac.uk/>).

An important role for miRNAs in the development of cancer has emerged in recent years (4). They are aberrantly expressed in many human cancers, and may function as oncogenes and tumor suppressors. A growing body of evidence indicates that unique miRNA expression profiles associated with particular cancers could serve as useful biomarkers for disease diagnosis and prognosis (5-7). Studies have been carried out for the purpose of identifying specific miRNA alterations in various cancers, including head and neck squamous cell carcinoma (HNSCC) (8-10).

Down-regulated miRNAs, including *miR-133a*, have been identified in bladder cancer and esophageal squamous cell carcinoma (ESCC) (11,12). Down-regulation of *miR-133a* has also been reported in HNSCC, and oral and colorectal cancers (7,13,14). The finding that over-expression of *miR-133a* reduces cell proliferation, migration and invasion suggested that *miR-133a* is a tumor suppressor (12,15). In this study, a screen for *miR-133a* target genes was performed using genome-wide expression analysis on HNSCC cell lines (HSC3 and SAS) transfected with *miR-133a*. Among the down-regulated genes, *caveolin-1* (*CAV1*) contained predicted binding sites for *miR-133a*.

Caveolins are a class of oligomeric structural proteins that are both necessary and sufficient for caveolae formation. Caveolae are 50- to 100-nm  $\omega$ -shaped invaginations of the plasma membrane that function as regulators of signal transduction. *CAV1* regulates multiple cancer-associated processes including cellular transformation, tumor growth, cell migration and metastasis, cell death and survival, multi-drug resistance and angiogenesis (16,17).

A luciferase reporter assay was used to determine if *CAV1* actually has *miR-133a* target sites. The functional significance of *CAV1* in HNSCC was also investigated using a loss-of-function assay. This is the first report that oncogenic *CAV1* is

---

*Correspondence to:* Dr Naohiko Seki, Department of Functional Genomics, Chiba University Graduate School of Medicine, 1-8-1 Inohana Chuo-ku, Chiba 260-8670, Japan  
E-mail: naoseki@faculty.chiba-u.jp

*Key words:* *miR-133a*, HNSCC, caveolin-1, migration, invasion

directly controlled by tumor suppressive microRNA, *miR-133a*, in HNSCC.

## Materials and methods

**Clinical HNSCC specimens and HNSCC cell culture.** Twenty-five pairs of primary HNSCC (oral cavity 11, larynx 3, oropharynx 5, and hypopharynx 6) and corresponding normal epithelial samples were obtained from patients in Chiba University Hospital (Chiba, Japan) from 2007 to 2009. All tissue specimens were obtained from patients undergoing surgical treatment. Normal tissues were obtained far from the center of the cancer in surgical specimens. No cancer cells were detected in neighboring formalin-fixed paraffin-embedded tissues. Written consent of tissue donation for research purposes was obtained from each patient before tissue collection. The protocol was approved by the Institutional Review Board of Chiba University. The specimens were immersed in RNAlater (Qiagen, Valencia, CA, USA) and stored at  $-20^{\circ}\text{C}$  until RNA was extracted. Human HNSCC cell lines (HSC3; derived from lymph node metastasis of tongue squamous cell carcinoma and SAS; derived from primary lesion of tongue squamous cell carcinoma) were provided by the American Type Culture Collection (ATCC, Manassas, VA, USA). Both cell lines were grown in Dulbecco's modified Eagle's medium/nutrient mixture F-12 Ham (DMEM/F-12) supplemented with 10% fetal bovine serum in a humidified atmosphere containing 5%  $\text{CO}_2$  at  $37^{\circ}\text{C}$ .

**RNA isolation.** Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. RNA concentrations were determined spectrophotometrically, and molecule integrity was checked by gel electrophoresis. RNA quality was confirmed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).

**Mature miRNA transfection and small interfering RNA treatment.** Mature miRNA molecules, Pre-miR<sup>TM</sup> miRNA precursors (hsa-miR-133a; P/N: AM17100 and negative control miRNA; P/N: AM17111), small interfering RNA, Silencer<sup>®</sup> Select siRNA; si-CAVI (P/N: s2446 and s2448) (Applied Biosystems, Foster City, CA, USA) and negative control siRNA (D-001810-10; Thermo Fisher Scientific, Waltham, MA, USA) were incubated with Opti-MEM (Invitrogen) and Lipofectamine<sup>TM</sup> RNAiMax reagent (Invitrogen) as described previously (11). Transfection efficiency of Pre-miR in cell lines was confirmed based on down-regulation of *PTK9* mRNA following transfection with *miR-1* (as recommended by the manufacturer).

**Cell proliferation, migration and invasion assays.** Cells were transfected with 10 nM siRNA by reverse transfection and plated into 96-well plates at  $3 \times 10^3$  cells per well. After 72 h, cell proliferation was determined by the XTT assay, using the Cell Proliferation Kit II (Roche Molecular Biochemicals, Mannheim, Germany) (12,18). Triplicate wells were measured for cell viability in each treatment group.

Cell migration activity was evaluated using a wound-healing assay. Cells were plated in 6-well dishes, and the cell

monolayer was scraped using a micropipette tip. The initial gap length (0 h) and the residual gap length, 24 h after wounding were calculated from photomicrographs (15).

A cell invasion assay was carried out using modified Boyden Chambers containing transwell-precoated matrigel membrane filter inserts with  $8\text{-}\mu\text{m}$  pores in 24-well tissue culture plates (BD Biosciences, Bedford, MA, USA) (15). All experiments were performed in triplicate.

**Target gene search for miR-133a.** A genome-wide screen using *miR-133a* transfectants was performed to identify target genes of *miR-133a* in two HNSCC cell lines, HSC3 and SAS. Oligo-microarray Human 44K (Agilent Technologies) was used for expression profiling in the transfectants in comparison with a miRNA-negative-control transfectant (12,15,18). Hybridization and wash steps were performed as previously described (19). The arrays were scanned using a Packard GSI Lumonics ScanArray 4000 (Perkin-Elmer, Boston, MA, USA). The data were analyzed by means of DNASIS array software (Hitachi Software Engineering, Tokyo, Japan), which converted the signal intensity for each spot into text format. The Log 2 ratios of the median subtracted background intensity were analyzed. Data from each microarray study were normalized by a global normalization method (19).

Predicted target genes and their target miRNA binding site seed regions were investigated using TargetScan (release 5.1, <http://www.targetscan.org/>). The sequences of the predicted mature miRNAs were confirmed using miRBase (release 16.0, <http://microrna.sanger.ac.uk/>).

**Real-time quantitative RT-PCR.** First-strand cDNA was synthesized from 1  $\mu\text{g}$  total RNA using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Gene-specific PCR products were assayed continuously using a 7900-HT Real-Time PCR System according to the manufacturer's protocol. The initial PCR step consisted of a 10-min hold at  $95^{\circ}\text{C}$ , followed by 40 cycles of a 15-sec denaturation at  $95^{\circ}\text{C}$  and a 1-min annealing/extension at  $63^{\circ}\text{C}$ . TaqMan<sup>®</sup> probes and primers for *CAVI* (P/N: Hs00971716\_m1) and the *GAPDH* (A/N: NM\_002046) internal control were obtained from Applied Biosystems (Assay-On-Demand Gene Expression Products). The expression levels of *miR-133a* (P/N: 002246) were analyzed by TaqMan quantitative real-time PCR (TaqMan MicroRNA Assay; Applied Biosystems) and normalized to *RNU48* (A/N: X96648). All reactions were performed in triplicate, and included negative control reactions that lacked cDNA.

**Immunoblotting.** Cells were harvested 72 h after transfection and lysates were prepared. Protein lysate (50  $\mu\text{g}$ ) was separated by NuPAGE on a 4-12% bis-tris gel (Invitrogen) and transferred to PVDF membranes. Immunoblotting was performed with diluted (1:100) monoclonal *CAVI* antibody (ab17052, Abcam, Cambridge, UK), with  $\beta$ -actin antibody (sc-1615; Santa Cruz Biotechnology, Santa Cruz, CA, USA) used as an internal control. The membrane was washed and incubated with goat anti-mouse IgG (H+L)-HRP conjugate (Bio-Rad, Hercules, CA, USA). Specific complexes were visualized by echochemiluminescence (GE Healthcare Bio-Sciences, Princeton, NJ, USA).

Table I. Top 25 genes down-regulated less than -2.00-fold in *miR-133a* transfectants.

No.	Entrez gene ID	Symbol	Gene name	Log 2 ratio			Target sites
				SAS	HSC3	Average	
1	63827	BCAN	Brevican	-3.80	-3.96	-3.88	-
2	10186	LHFP	Lipoma HMGIC fusion partner	-2.97	-4.53	-3.75	+
3	857	CAV1	Caveolin 1, caveolae protein, 22 kDa	-2.59	-4.85	-3.72	+
4	7431	VIM	Vimentin	-3.58	-3.47	-3.53	-
5	10970	CKAP4	Cytoskeleton-associated protein 4	-2.49	-4.46	-3.48	+
6	1070	CETN3	Centrin, EF-hand protein, 3 (CDC31 homolog, yeast)	-2.48	-4.33	-3.41	+
7	1295	COL8A1	Collagen, type VIII, $\alpha$ 1	-3.40	3.38	-3.39	-
8	359821	MRPL42P5	Mitochondrial ribosomal protein L42 pseudogene 5	-3.40	-3.29	-3.35	-
9	55425	KIAA1704	KIAA1704	-2.54	-4.09	-3.31	-
10	121457	IKIP	IKBKB interacting protein	-3.05	-3.56	-3.30	-
11	7168	TPM1	Tropomyosin 1 ( $\alpha$ )	-3.28	-3.28	-3.28	-
12	23621	BACE1	$\beta$ -site APP-cleaving enzyme 1	-3.35	-2.88	-3.11	+
13	5923	RASGRF1	Ras protein-specific guanine nucleotide-releasing factor 1	-2.49	-3.67	-3.08	-
14	79026	AHNAK	AHNAK nucleoprotein	-3.33	-2.83	-3.08	-
15	8835	SOCS2	Suppressor of cytokine signaling 2	-1.95	-4.18	-3.07	-
16	255758	MGC33212	Tctex1 domain containing 2	-3.00	-3.10	-3.05	-
17	63920	LOC63920	Chromosome 5 open reading frame 54	-1.92	-4.07	-3.00	-
18	7424	VEGFC	Vascular endothelial growth factor C	-1.84	-4.11	-2.97	+
19	83879	CDCA7	Cell division cycle associated 7	-1.42	-4.51	-2.96	-
20	667	DST	Dystonin	-1.91	-4.01	-2.96	+
21	200894	ARL13B	ADP-ribosylation factor-like 13B	-1.85	-4.05	-2.95	+
22	1063	CENPF	Centromere protein F, 350/400 ka (mitosin)	-1.49	-4.37	-2.93	-
23	79827	ASAM	Adipocyte-specific adhesion molecule	-2.83	-2.99	-2.91	-
24	29843	SENP1	SUMO1/sentrin specific peptidase 1	-2.24	-3.55	-2.89	+
25	2760	GM2A	GM2 ganglioside activator	-3.00	-2.78	-2.89	-

**Plasmid construction and dual-luciferase assay.** *miR-133a* target sequences were inserted between the *XhoI* and *PmeI* restriction sites in the 3'UTR of the hRluc gene in the psiCHECK-2 vector (Promega, Madison, WI, USA). The amplified fragment was cloned into the psiCHECK-2 vector and confirmed by sequencing using the following primers: 5'-ACCGAGTTCGTGAAGGTGAA-3' and 5'-CAAACCCTAACCACCGCTTA-3'. SAS cells were then transfected with 5 ng vector, 10 nM mature miRNA molecules, Pre-miRNA<sup>TM</sup> *miR-133a* (Applied Biosystems), and 1  $\mu$ l Lipofectamine 2000 (Invitrogen) in 100  $\mu$ l Opti-MEM<sup>TM</sup>. Firefly and Renilla luciferase activities in cell lysates were determined using a dual-luciferase assay system (Promega). Normalized data were calculated as the quotient of Renilla/firefly luciferase activities.

**Statistical analysis.** The relationships between two groups and the numerical values obtained by real-time RT-PCR were analyzed using the non-parametric Mann-Whitney's U test or the paired t-test. The relationship among three variables and numerical values was analyzed using the Bonferroni-adjusted Mann-Whitney's U test; a non-adjusted statistical level of

significance of  $P < 0.05$  corresponded to a Bonferroni-adjusted level of  $P < 0.0167$ . All analyses were performed using Expert StatView (version 4, SAS Institute Inc., Cary, NC, USA).

## Results

**Identification of *miR-133a* target genes by genome-wide expression analysis.** To investigate the molecular basis of candidate targets of *miR-133a* in HNSCC cells, we examined the effect of *miR-133a* on protein-coding genes. Mature *miR-133a* was transiently transfected into HSC3 and SAS cells, with negative-miRNA transfection used as a control. Comprehensive gene expression analysis (see Materials and methods) clearly showed changes in gene expression patterns between *miR-133a* and negative-control transfectants. To identify candidate *miR-133a* target genes, a cut-off of values less than -2.00-fold was applied to the array data. This filtering resulted in the identification of 164 genes that were significantly down-regulated upon *miR-133a* transfection both HSC3 and SAS cells (top 25 genes were shown; Table I). Entries from the microarray data were approved by the Gene Expression




Figure 1. *CAVI* mRNA expression levels from clinical specimens and HNSCC cell lines. *miR-133a* expression levels of clinical specimens. (A) *CAVI* mRNA expression of tumor tissues and normal adjacent tissues in 25 clinical HNSCC specimens. (B) *CAVI* expression in two HNSCC cell lines (HSC3 and SAS) was evaluated by real-time RT-PCR. The expression level of normal adjacent tissues was used as a reference. (C) *miR-133a* expression of normal adjacent tissues and tumor tissues in 25 clinical specimens of HNSCC.

Table II. Clinical features of HNSCC patients.

No.	Gender	Age	Location	Differentiation	T	N	M	Stage
1	Male	60	Oral	Well	2	0	0	II
2	Male	60	Oral	Moderate	4a	2c	0	IV A
3	Male	66	Oral	Moderate	2	0	0	II
4	Female	73	Oral	Well	1	0	0	I
5	Male	64	Oral	Well	1	0	0	I
6	Male	66	Oral	Well	3	0	0	III
7	Male	58	Oral	Moderate	1	0	0	I
8	Male	65	Oral	Moderate	4a	1	0	IV A
9	Male	73	Oral	Poor	3	1	0	III
10	Female	38	Oral	Well	2	2b	0	IV A
11	Male	67	Oral	Moderate	4a	2c	0	IV A
12	Male	66	Larynx	Well	4a	0	0	IV
13	Male	69	Larynx	Well	3	0	0	III
14	Male	57	Larynx	Moderate	4a	0	0	III
15	Male	64	Oropharynx	Poor	3	2c	0	IV A
16	Male	77	Oropharynx	Moderate	4b	2b	0	IV B
17	Male	76	Oropharynx	Poor	2	0	0	II
18	Male	52	Oropharynx	Moderate	3	2a	0	IV A
19	Female	65	Oropharynx	Well	4a	2b	0	IV A
20	Female	65	Hypopharynx	Well	4a	0	0	IV A
21	Male	68	Hypopharynx	Poor	4a	1	0	IV A
22	Male	68	Hypopharynx	Moderate	4a	1	0	IV A
23	Male	61	Hypopharynx	Moderate	4a	2c	0	IV A
24	Male	66	Hypopharynx	Moderate	2	2c	0	IV A
25	Female	74	Hypopharynx	Well	4a	0	0	IV A




Figure 2. Regulation of *CAV1* expression in *miR-133a* transfectants. (A) *CAV1* mRNA expression was repressed in *miR-133a* transfectants. \* $P < 0.05$ . (B) The protein expression level of *CAV1* was also repressed in *miR-133a* transfectants.

Omnibus (GEO), and were assigned the GEO accession number GSE20028.

The 3'UTR regions of these down-regulated genes were examined for *miR-133a* target sites using the TargetScan database. Of the top 25 putative gene targets, 9 genes contained *miR-133a* target sites.

*CAV1* mRNA and *miR-133a* expression in HNSCC clinical specimens. The expression level of *CAV1* mRNA was up-regulated in clinical HNSCC specimen compared with adjacent normal tissues (Fig. 1A). *CAV1* mRNA expressions in HNSCC cell lines were also over-expressed relative to normal epithelia (Fig. 1B). Conversely, *miR-133a* was down-regulated in tumor tissues (Fig. 1C). Characteristic data of 25 HNSCC patients are described in Table II.

*CAV1* as a target of post-transcriptional repression by *miR-133a*. *CAV1* was the third-ranked candidate gene in the genome-wide gene expression analysis. We focused on *CAV1*,

not first- or second-ranked genes, because the latter were not reported in association with HNSCC.

The expression level of *CAV1* mRNA was significantly decreased in the two HNSCC cell lines (HSC3 and SAS) transfected with *miR-133a* (Fig. 2A). The protein expression level was also markedly reduced in *miR-133a* transfectants (Fig. 2B). SAS cells were used to determine the effect of *miR-133a* suppression on *CAV1* expression. The TargetScan database identified two putative target sites in the 3'UTR of *CAV1* (Fig. 3, upper). A luciferase reporter assay confirmed the 3'UTR of *CAV1* as the actual target of *miR-133a*. Luciferase activity was significantly decreased in two *miR-133a* target sites (position 735-741 and 888-894 in 3'UTR of *CAV1*) (Fig. 3, lower).

*Effect of CAV1 silencing on cell proliferation, migration and invasion activity in HNSCC cell lines.* A loss-of-function assay using siRNA analysis was performed to examine the oncogenic function of *CAV1* in the presence of *miR-133a*. We determined




Figure 3. Putative target sites in the *CAVI* 3'UTR were identified with the TargetScan database: two target sites for *miR-133a*. The Renilla luciferase values were normalized against firefly luciferase values. \*P<0.05.




Figure 4. Effect of *CAVI* knockdown on HNSCC cells. (A) RT-PCR revealed that *CAVI* mRNA was markedly repressed in si-*CAVI* transfectants compared with the controls. \*P<0.0001. (B) Western blotting revealed that *CAVI* protein was also decreased in si-*CAVI* transfectants compared with the controls.




Figure 5. Loss-of-function studies using si-CAV1 transfected HNSCC cell lines. (A) Cell growth as revealed by the XTT assay; (B) Cell migration activity (wound healing assay); (C) Cell invasion activity (matrigel invasion assay) in HSC-3 transfected with si-CAV1.

whether si-CAV1 reduced both mRNA and protein expression levels of si-CAV1 transfectants in HNSCC cell lines, HSC3 and SAS. CAV1 mRNA and protein were reduced following a 72-h transfection with si-CAV1 (Fig. 4). The XTT assay revealed no significant cell growth inhibition in the si-CAV1 transfectants compared with siRNA control transfectants (Fig. 5A). The wound healing assay demonstrated that cell migration was inhibited by si-CAV1 (% of wound closure; control:  $100.0 \pm 8.1$ , si-CAV1-1:  $68.4 \pm 4.1$ , si-CAV1-2:  $59.7 \pm 5.9$ , Fig. 5B), and the matrigel invasion assay showed that the number of invading cells was significantly decreased in si-CAV1 transfectants (invading cell numbers; control:  $230.3 \pm 20.7$ , si-CAV1-1:  $176.2 \pm 15.4$ , si-CAV1-2:  $47.1 \pm 4.9$ , Fig. 5C).

## Discussion

Aberrant expression of miRNAs has been associated with the development of various cancers. To date, studies have been carried out for the purpose of identifying specific miRNA alterations in various cancers, including HNSCC (8-10). Recently, we reported several down-regulated miRNAs have

been found in the expression signatures of bladder cancer and ESCC (11,12). Expression studies revealed a reduction in *miR-133a* levels in many types of cancers (7,11-14,20-22). Consistent with these earlier studies, we found significant inhibition of cell growth, migration and invasion in ESCC and bladder cancer cell lines transfected with *miR-133a* (12,15). These results strongly suggest that *miR-133a* functions as a tumor suppressor. Consequently, we focused on *miR-133a* and continued the analysis of the molecular mechanism of *miR-133a* and HNSCC oncogenesis.

A new class of regulatory molecules known as miRNAs is redefining our understanding of the molecular pathways associated with carcinogenesis. Bioinformatic predictions indicate that miRNAs regulate more than 30% of the protein coding genes (3). We adopted a method of genome-wide gene expression analysis using specific miRNA transfectants and searched for targets of *miR-133a* in HNSCC cell lines. Using this strategy in several cancer cell lines led to the identification of tumor suppressive miRNA targets (12,15,23). *CAV1* was significantly down-regulated by *miR-133a* over-expression in HNSCC cell lines. The luciferase reporter assay revealed that *CAV1* contains sites targeted by *miR-133a*. This is the first

report that tumor suppressive *miR-133a* directly regulates *CAVI* in cancer cells. Published articles of *miR-133a* targets include *miR-133a* inhibited proliferation and induced apoptosis in SCC of the tongue, and directly controlled pyruvate kinase type M2 expression (20). A search for tumor suppressive miRNA targets is important for elucidation of the molecular network of HNSCC progression, to which our expression signature of *miR-133a* target analysis will contribute.

Caveolins are a basic constituent of  $\omega$ -shaped cell membrane microdomains called caveolae. Several heterogeneous functions are attributed to caveolae and their proteins, including vesicular transport and cholesterol homeostasis (17,24). A scaffolding amino acid sequence identified in *CAVI* allows this protein to interact with signaling molecules such as epidermal growth factor receptor, G-proteins, c-Src-like kinases, HA-Ras, protein kinase C, endothelial nitric-oxide synthase, and integrin (16,25-27). In fact, in several types of cancer cells, *CAVI* has been associated and/or co-localized with epidermal growth factor receptor (EGFR) and modulate EGFR signaling (28,29). In A549 lung cancer cells, EGFR and *CAVI* co-localize in the cell membrane, where *CAVI* may have a role in carcinogenesis via EGFR activation, transport to its perinuclear location, and activation maintenance (30,31).

Over-expression of *CAVI* has been reported in nasopharyngeal cancer, ESCC, urological cancer, prostate cancer and gliomas. Up-regulation of *CAVI* is associated with more aggressive behavior, increased recurrence rate and poorer prognosis (32-36). Increased *CAVI* expression has recently been reported in multidrug-resistant neoplastic cells, suggesting its specific role in the acquisition and maintenance of this phenotype (37,38). In this study, a loss-of-function study using si-*CAVI* in HNSCC cell lines revealed that *CAVI* mediates cell migration and invasion. In contrast, *CAVI* appears to be a suppressor of metastatic breast cancer when expression is inhibited (39,40). In HNSCC cell lines, over-expression of *CAVI* may play an inhibitory role in carcinogenesis and lung metastasis through regulation of integrin  $\beta$ 1- and Src-mediated cell-cell and cell-matrix interactions (41). *CAVI* expression has been studied in several cancers, in which expression patterns were either reduced, up-regulated or unchanged; therefore, its role in cancer is still debated and highly controversial (17,24,42). Further analysis of the downstream signaling pathways of *CAVI* in different cancer cell types is needed to solve these contradictions.

Epithelial to mesenchymal transitions (EMT) are critical for the invasion, progression, and metastasis of epithelial carcinogenesis. Cancer cells that undergo EMT, acquire various types of malignant ability, such as invasion and metastasis to lymph node or distant organ (43,44). However, the role of EMT in HNSCC remains unexplored. Over-expression of *CAVI* during EMT showed tight regulation by focal adhesion kinase (FAK). It also demonstrated that FAK-mediated *CAVI* up-regulation was involved in cell adhesion and motility (44).

How *CAVI* expression changes in many types of cancers is still unclear, but one possible mechanism is through regulation by miRNAs. Loss of *miR-133a*, an endogenous *CAVI* inhibitor, may promote aberrant expression of *CAVI* in cancer cells, including HNSCC, contributing to pathogenesis and cancer progression. Down-regulation of *miR-133a* and over-expres-

sion *CAVI* were identified in HNSCC, which suggests that this tumor suppressive miRNA and oncogenic mRNA pathway may be an important therapeutic target for human cancers.

## Acknowledgements

This study was supported by the Ministry of Education, Science, Sports and Culture, Grant-in-Aid for Scientific Research (C), 21592187.

## References

- Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* 116: 281-297, 2004.
- Kloosterman WP and Plasterk RH: The diverse functions of microRNAs in animal development and disease. *Dev Cell* 11: 441-450, 2006.
- Filipowicz W, Bhattacharyya SN and Sonenberg N: Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? *Nat Rev Genet* 9: 102-114, 2008.
- Hwang HW and Mendell JT: MicroRNAs in cell proliferation, cell death, and tumorigenesis. *Br J Cancer* 94: 776-780, 2006.
- Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR and Golub TR: MicroRNA expression profiles classify human cancers. *Nature* 435: 834-838, 2005.
- Calin GA and Croce CM: MicroRNA signatures in human cancers. *Nat Rev Cancer* 6: 857-866, 2006.
- Childs G, Fazzari M, Kung G, Kawachi N, Brandwein-Gensler M, McLemore M, Chen Q, Burk RD, Smith RV, Prystowsky MB, Belbin TJ and Schlecht NF: Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. *Am J Pathol* 174: 736-745, 2009.
- Liu X, Chen Z, Yu J, Xia J and Zhou X: MicroRNA profiling and head and neck cancer. *Comp Funct Genomics* 2009: 837514 Epub 2009, PMID: 19753298.
- Tran N, O'Brien CJ, Clark J and Rose B: Potential role of microRNAs in head and neck tumorigenesis. *Head Neck* 32: 1099-1111, 2010.
- Cho WC: MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. *Int J Biochem Cell Biol* 42: 1273-1281, 2010.
- Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, Kawamoto K, Kawahara K, Toki K, Kawakami K, Nishiyama K, Tsujimoto G, Nakagawa M and Seki N: Identification of novel microRNA targets based on microRNA signatures in bladder cancer. *Int J Cancer* 125: 345-352, 2009.
- Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M and Matsubara H: miR-145, miR-133a and miR-133b: tumor suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. *Int J Cancer* [Epub ahead of print] PMID: 20198616.
- Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP and Wei WI: Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. *Clin Cancer Res* 14: 2588-2592, 2008.
- Arndt GM, Dossey L, Cullen LM, Lai A, Druker R, Eisbacher M, Zhang C, Tran N, Fan H, Retzlaff K, Bittner A and Raponi M: Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. *BMC Cancer* 9: 374, 2009.
- Chiyomaru T, Enokida H, Tatarano S, Kawahara K, Uchida Y, Nishiyama K, Fujimura L, Kikkawa N, Seki N and Nakagawa M: miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. *Br J Cancer* 102: 883-891, 2010.
- Liu P, Rudick M and Anderson RG: Multiple functions of caveolin-1. *J Biol Chem* 277: 41295-41298, 2002.
- Goetz JG, Lajoie P, Wiseman SM and Nabi IR: Caveolin-1 in tumor progression: the good, the bad and the ugly. *Cancer Metastasis Rev* 27: 715-735, 2008.
- Kikkawa N, Hanazawa T, Fujimura L, Nohata N, Suzuki H, Chazono H, Sakurai D, Horiguchi S, Okamoto Y and Seki N: miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma (HSCC). *Br J Cancer* 103: 877-884, 2010.



19. Sugimoto T, Seki N, Shimizu S, Kikkawa N, Tsukada J, Shimada H, Sasaki K, Hanazawa T, Okamoto Y and Hata A: The galanin signaling cascade is a candidate pathway regulating oncogenesis in human squamous cell carcinoma. *Genes Chromosomes Cancer* 48: 132-142, 2009.
20. Wong TS, Liu XB, Chung-Wai Ho A, Po-Wing Yuen A, Wai-Man Ng R and Ignace Wei W: Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling. *Int J Cancer* 123: 251-257, 2008.
21. Rao PK, Missiaglia E, Shields L, Hyde G, Yuan B, Shepherd CJ, Shipley J and Lodish HF: Distinct roles for miR-1 and miR-133a in the proliferation and differentiation of rhabdomyosarcoma cells. *FASEB J* 24: 3427-3437, 2010.
22. Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A, Labourier E and Hahn SA: MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. *Oncogene* 26: 4442-4452, 2007.
23. Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Uchida Y, Kawahara K, Nishiyama K, Seki N and Nakagawa M: Functional role of LASP1 in cell viability and its regulation by microRNAs in bladder cancer. *Urol Oncol* [Epub ahead of print] PMID: 20843712.
24. Carver LA and Schnitzer JE: Caveolae: mining little caves for new cancer targets. *Nat Rev Cancer* 3: 571-581, 2003.
25. Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B, Menne J, Lindschau C, Mende F, Luft FC, Schedl A, Haller H and Kurzchalia TV: Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. *Science* 293: 2449-2452, 2001.
26. Okamoto T, Schlegel A, Scherer PE and Lisanti MP: Caveolins, a family of scaffolding proteins for organizing 'preassembled signaling complexes' at the plasma membrane. *J Biol Chem* 273: 5419-5422, 1998.
27. Razani B, Altschuler Y, Zhu L, Pestell RG, Mostov KE and Lisanti MP: Caveolin-1 expression is down-regulated in cells transformed by the human papilloma virus in a p53-dependent manner. Replacement of caveolin-1 expression suppresses HPV-mediated cell transformation. *Biochemistry* 39: 13916-13924, 2000.
28. Abulrob A, Giuseppin S, Andrade MF, McDermid A, Moreno M and Stanimirovic D: Interactions of EGFR and caveolin-1 in human glioblastoma cells: evidence that tyrosine phosphorylation regulates EGFR association with caveolae. *Oncogene* 23: 6967-6979, 2004.
29. Couet J, Sargiacomo M and Lisanti MP: Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. *J Biol Chem* 272: 30429-30438, 1997.
30. Khan EM, Heidinger JM, Levy M, Lisanti MP, Ravid T and Goldkorn T: Epidermal growth factor receptor exposed to oxidative stress undergoes Src- and caveolin-1-dependent perinuclear trafficking. *J Biol Chem* 281: 14486-14493, 2006.
31. Dittmann K, Mayer C, Kehlbach R and Rodemann HP: Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK. *Mol Cancer* 7: 69, 2008.
32. Du ZM, Hu CF, Shao Q, Huang MY, Kou CW, Zhu XF, Zeng YX and Shao JY: Upregulation of caveolin-1 and CD147 expression in nasopharyngeal carcinoma enhanced tumor cell migration and correlated with poor prognosis of the patients. *Int J Cancer* 125: 1832-1841, 2009.
33. Kato K, Hida Y, Miyamoto M, Hashida H, Shinohara T, Itoh T, Okushiba S, Kondo S and Katoh H: Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. *Cancer* 94: 929-933, 2002.
34. Satoh T, Yang G, Egawa S, Addai J, Frolov A, Kuwao S, Timme TL, Baba S and Thompson TC: Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients. *Cancer* 97: 1225-1233, 2003.
35. Campbell L, Gumbleton M and Griffiths DF: Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma. *Br J Cancer* 89: 1909-1913, 2003.
36. Forget MA, Desrosiers RR, Del M, Moumdjian R, Shedid D, Berthelet F and Beliveau R: The expression of rho proteins decreases with human brain tumor progression: potential tumor markers. *Clin Exp Metastasis* 19: 9-15, 2002.
37. Ho CC, Kuo SH, Huang PH, Huang HY, Yang CH and Yang PC: Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy. *Lung Cancer* 59: 105-110, 2008.
38. Lavie Y, Fiucci G and Liscovitch M: Upregulation of caveolin in multidrug resistant cancer cells: functional implications. *Adv Drug Deliv Rev* 49: 317-323, 2001.
39. Fiucci G, Ravid D, Reich R and Liscovitch M: Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. *Oncogene* 21: 2365-2375, 2002.
40. Lee SW, Reimer CL, Oh P, Campbell DB and Schnitzer JE: Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. *Oncogene* 16: 1391-1397, 1998.
41. Zhang H, Su L, Muller S, Tighiouart M, Xu Z, Zhang X, Shin HJ, Hunt J, Sun SY, Shin DM and Chen ZG: Restoration of caveolin-1 expression suppresses growth and metastasis of head and neck squamous cell carcinoma. *Br J Cancer* 99: 1684-1694, 2008.
42. Williams TM and Lisanti MP: Caveolin-1 in oncogenic transformation, cancer, and metastasis. *Am J Physiol Cell Physiol* 288: C494-C506, 2005.
43. Mandal M, Myers JN, Lippman SM, Johnson FM, Williams MD, Rayala S, Ohshiro K, Rosenthal DI, Weber RS, Gallick GE and El-Naggar AK: Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features. *Cancer* 112: 2088-2100, 2008.
44. Bailey KM and Liu J: Caveolin-1 up-regulation during epithelial to mesenchymal transition is mediated by focal adhesion kinase. *J Biol Chem* 283: 13714-13724, 2008.